DiaMedica Therapeutics (DMAC) Earnings Date, Estimates & Call Transcripts $6.00 +0.78 (+14.94%) Closing price 04:00 PM EasternExtended Trading$6.01 +0.01 (+0.17%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DiaMedica Therapeutics Earnings Summary DiaMedica Therapeutics issued Q2 2025 earnings on August 12, 2025, reporting an EPS of -$0.18, which hit the consensus estimate of -$0.18. With a trailing EPS of -$0.64, DiaMedica Therapeutics' earnings are expected to decrease next year, from ($0.59) to ($0.80) per share. Latest Q2 Earnings DateAug. 12ConfirmedConsensus EPS (Aug. 12) -$0.18 Actual EPS (Aug. 12) -$0.18 Q2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get DiaMedica Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DiaMedica Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataDMAC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. DiaMedica Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.18-$0.18-$0.18Q2 20251-$0.18-$0.18-$0.18Q3 20251-$0.18-$0.18-$0.18Q4 20251-$0.18-$0.18-$0.18 DiaMedica Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025-$0.18-$0.18--$0.18--5/13/2025Q1 2025-$0.18-$0.18--$0.18--3/17/2025Q4 2024-$0.17-$0.18 -$0.01-$0.18--8/7/2024Q2 2024-$0.16-$0.13+$0.03-$0.13--5/8/2024Q1 2024-$0.16-$0.14+$0.02-$0.14--3/20/2024--$0.14-$0.14--$0.14--11/13/2023Q3 2023-$0.14-$0.12+$0.02-$0.12--8/14/2023Q2 2023-$0.22-$0.16+$0.06-$0.16-- DiaMedica Therapeutics Earnings - Frequently Asked Questions When did DiaMedica Therapeutics announce their last quarterly earnings? DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earning data on Tuesday, August 12, 2025. Learn more on DMAC's earnings history. Did DiaMedica Therapeutics beat their earnings estimates last quarter? In the previous quarter, DiaMedica Therapeutics (NASDAQ:DMAC) reported ($0.18) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.18). Learn more on analysts' earnings estimate vs. DMAC's actual earnings. How can I listen to DiaMedica Therapeutics' earnings conference call? The conference call for DiaMedica Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read DiaMedica Therapeutics' conference call transcript? The conference call transcript for DiaMedica Therapeutics' latest earnings report can be read online. Read Transcript How much profit does DiaMedica Therapeutics generate each year? DiaMedica Therapeutics (NASDAQ:DMAC) has a recorded net income of -$24.44 million. DMAC has generated -$0.64 earnings per share over the last four quarters. What is DiaMedica Therapeutics' EPS forecast for next year? DiaMedica Therapeutics' earnings are expected to decrease from ($0.59) per share to ($0.80) per share in the next year. More Earnings Resources from MarketBeat Related Companies Stoke Therapeutics Earnings Date Vir Biotechnology Earnings Date Amylyx Pharmaceuticals Earnings Date Day One Biopharmaceuticals Earnings Date Dianthus Therapeutics Earnings Date KalVista Pharmaceuticals Earnings Date Maze Therapeutics Earnings Date ArriVent BioPharma Earnings Date Mind Medicine (MindMed) Earnings Date Arbutus Biopharma Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? This page (NASDAQ:DMAC) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access